Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Short summary

In patients with type 2 diabetes and high cardiovascular risk, empagliflozin added to standard care significantly reduced the primary composite outcome of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 14% (hazard ratio, 0.86) over a median of 3.1 years.

AI-generated from the title and abstract; the full text is not read.